DRUG · Mapped RxNorm record
Docetaxel
Normalized identity: docetaxelView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer
NCT00134706
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Carboplatin
Normalized identity: carboplatinView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Prostate Cancerverified · MONDO: prostate cancer
Interventions
DocetaxelDRUG · verified · RxNorm: docetaxel
CarboplatinDRUG · verified · RxNorm: carboplatin
Sponsors & collaborators
Dana-Farber Cancer Institutelead sponsor
Bristol-Myers Squibbcollaborator
Beth Israel Deaconess Medical Centercollaborator
Lowell General Hospitalcollaborator
Massachusetts General Hospitalcollaborator
Oregon Health and Science Universitycollaborator
Wentworth-Douglass Hospitalcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00134706 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.